S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators
Autor(en): | Heppt, M.V. Leiter, U. Steeb, T. Amaral, T. Bauer, A. Becker, J.C. Breitbart, E. Breuninger, H. Diepgen, T. Dirschka, T. Eigentler, T. Flaig, M. Follmann, M. Fritz, K. Greinert, R. Gutzmer, R. Hillen, U. Ihrler, S. John, S.M. Kölbl, O. Kraywinkel, K. Löser, C. Nashan, D. Noor, S. Nothacker, M. Pfannenberg, C. Salavastru, C. Schmitz, L. Stockfleth, E. Szeimies, R.-M. Ulrich, C. Welzel, J. Wermker, K. Berking, C. Garbe, C. |
Stichwörter: | diclofenac, 15307-79-6, 15307-86-5; fluorouracil, 51-21-8; imiquimod, 99011-02-6; ingenol mebutate, 75567-37-2; diclofenac; fluorouracil; imiquimod; ingenol mebutate; retinoid; topical agent, actinic keratosis; Article; chemexfoliation; clinical decision making; cryosurgery; diagnostic procedure; disease classification; disease course; echography; general practitioner; graft recipient; health care quality; human; immunocompromised patient; low level laser therapy; photodynamic therapy; practice guideline; skin carcinoma; thorax radiography; treatment indication | Erscheinungsdatum: | 2020 | Herausgeber: | Wiley-VCH Verlag | Journal: | JDDG - Journal of the German Society of Dermatology | Volumen: | 18 | Ausgabe: | 3 | Startseite: | 275 | Seitenende: | 294 | Zusammenfassung: | Actinic keratoses (AK) are common lesions in light-skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence-based framework for clinical decision making, the guideline “actinic keratosis and cutaneous squamous cell carcinoma” was developed using the highest level of methodology (S3) according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF). The guideline is aimed at dermatologists, general practitioners, ENT specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office-based settings as well as other medical specialties involved in the diagnosis and treatment of patients with AK and cSCC. The guideline is also aimed at affected patients, their relatives, policy makers and insurance funds. In the first part, we will address aspects relating to diagnosis, interventions for AK, care structures and quality-of-care indicators. © 2020 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft. |
ISSN: | 16100379 | DOI: | 10.1111/ddg.14048 | Externe URL: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080985028&doi=10.1111%2fddg.14048&partnerID=40&md5=8e5520184f89fbdad39a7fa0b2539876 |
Zur Langanzeige
Seitenaufrufe
3
Letzte Woche
0
0
Letzter Monat
0
0
geprüft am 05.05.2024